Instrumento Inactivo

Otros idiomas Kyowa Hakko Kirin Co Ltd BOERSE MUENCHEN

Acciones

Precio de cierre BOERSE MUENCHEN Otros sitios de cotización
- ^EUR	-

07/05	Los beneficios de Kyowa Kirin aumentan un 15% en el primer trimestre	MT
02/05	Las acciones de BridgeBio Pharma bajan tras los resultados financieros del 1T	MT

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Kyowa Kirin Repurchases 3.3 Million Shares in May	05/06
Kyowa Kirin : Announces Approval for Partial Change of Approved Indication of G-Lasta® for the Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Blood Stem Cell Transplantation in Japan (243KB)	17/05
Kyowa Kirin : Transcript of Results Briefing Fiscal 2024 First Quarter (0B)	09/05
Kyowa Kirin's Profit Up 15% in Q1	07/05
Kyowa Kirin : Results Presentation Fiscal 2024 First Quarter (0B)	07/05
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List	06/05
Kyowa Kirin Buys Back Shares for 5.6 Billion Yen in April	06/05
BridgeBio Pharma Shares Decline After Q1 Financial Results	02/05
Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ (istradefylline) and Other Parkinson's Disease Add-On Therapies	15/04
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome	15/04
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	08/04
Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March	03/04
Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	02/04
Japanese Shares Slip into Red Amid Profit-Taking; Tokyo Inflation Eyed	25/03
Kyowa Kirin to Allocate Over 84,000 Treasury Shares as Director, Officer Compensation	25/03
Kyowa Kirin's gene therapy most expensive US drug with $4.3 million price tag	20/03
US approves first gene therapy for children with rare genetic disease	18/03
US approves first gene therapy for rare genetic disease	18/03
Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024	11/03
Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024	08/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Kyowa Hakko Kirin Co Ltd BOERSE MUENCHEN

Acciones

Otros idiomas

Filtros